Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis

Yano, Hideki; Horinaka, Shigeo; Yagi, Hiroshi; Ishimitsu, Toshihiko

doi:10.1007/s00380-012-0250-9

Cited by 12 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calabró et al [34] reported that IL-1β and IL-6 stimulated CRP production in cultured human coronary artery smooth muscle cells. The concentrations of IL-1β and IL-6 used in their experiments were also more than 1,000 times that of the PCI-associated pathophysiological ranges detected in our study and others [32]. VSMCs in vessels induced by inflammatory cytokines at the PCI-associated pathophysiological range were not able to express CRP.…”

Section: Discussionmentioning

confidence: 82%

“…This indicates that the coronary arteries with stent implantation do not seem to produce many inflammatory markers. This phenomenon might be the result of the local inhibition effect of rapamycin (in the stent) on the vessel, or due to the stent encapsulating completely or partially with connective tissue and endothelial cells [32,33]. Acute inflammation (including noninfectious inflammation) from PCI increases the secretion of the cytokines IL-6 and IL-1β, which in turn encourage CRP expression mainly in the liver through different signaling pathways.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

C-Reactive Protein and Inflammatory Cytokines during Percutaneous Coronary Intervention

Gu²,

Li³

et al. 2016

J Vasc Res

View full text Add to dashboard Cite

Background: C-reactive protein (CRP) is significantly associated with cardiovascular diseases; however, whether CRP plays a causal role in coronary artery disease has yet to be determined. In addition, the relationship between CRP, atherosclerosis, and inflammation remains controversial. Methods and Results: Serum interleukin (IL)-6, IL-1β, and CRP levels were determined in 160 patients at time points around percutaneous coronary intervention (PCI) with drug-eluting stent implantation. The levels were found to be at peak at 24 h post-PCI and gradually declined to the level before PCI at day 30 post-PCI. These inflammation markers around PCI have no statistical difference in the different postdilation pressures (≤14, 14-18, and ≥18 atm) and stent number (1 and ≥2 stents) groups. Treatment of cultured human vascular smooth muscle cells (VSMCs) with a combination of IL-6 and IL-1β at concentrations associated with PCI did not result in any significant change in the CRP mRNA levels. The IL-6-augmented CRP expression in human internal mammary arteries (IMAs) stretched with a mechanical strength of 3 g was blocked by the nuclear factor-κB (NF-κB) peptide inhibitor SN50 and not by the inactive SN50 analog SN50M. IL-6 treatment increased NF-κB activity in human IMAs stretched with 3 g, and this effect was further blocked by stretch-activated channel (SAC) inhibitors (streptomycin or GdCl₃) and SN50. Conclusions: The current study provides evidence that increased serum IL-6, IL-1β, and CRP levels around PCI are not different between different postdilation pressure and stent number groups. The combination of IL-6 and IL-1β at concentrations associated with PCI cannot induce CRP expression in human VSMCs, but they can augment mechanical strain-induced CRP synthesis via the SAC-NF-κB pathway in human IMAs.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

C-Reactive Protein and Inflammatory Cytokines during Percutaneous Coronary Intervention

Gu²,

Li³

et al. 2016

J Vasc Res

View full text Add to dashboard Cite

show abstract

“…However, Pencak et al [8] suggested that the time on HD therapy (per year) was an independent risk factor that favored the occurrence of coronary artery calcification by the computed tomography assessment, and in our data, the calcified lesions were more frequently observed in the long HD duration group. Several mechanisms such as disturbances in mineral metabolism, oxidative stress, inflammation, and neoangiogenesis have been recognized as causes of atherosclerosis progression in HD patients [16,17].…”

Section: Discussionmentioning

confidence: 99%

Influence of hemodialysis duration on mid-term clinical outcomes in hemodialysis patients with coronary artery disease after drug-eluting stent implantation

et al. 2014

View full text Add to dashboard Cite

Accelerated atherosclerosis in prolonged maintenance hemodialysis (HD) has been recognized; however, whether HD duration is associated with poor clinical outcome in HD patients with coronary artery disease (CAD) after drug-eluting stent (DES) implantation is unknown. We evaluated the impact of HD duration on clinical outcomes in HD patients with CAD after DES implantation. Between April 2007 and December 2012, 168 angina pectoris patients (320 de novo lesions) on HD were treated with DES. Major adverse cardiovascular events (MACE) and target lesion revascularization (TLR) were investigated at 3 years according to the HD duration (≤ 3 years, 83 patients; >3 years, 85 patients). The incidence of MACE was significantly higher in the long HD duration group (25.3 vs. 50.6 %; P = 0.001). Especially, sudden cardiac death (SCD) was significantly higher in the long HD duration group (3.6 vs. 16.5 %; P = 0.006). On the other hand, the rates of TLR were similar between the two groups (12.0 vs. 14.1 %; P = 0.69). Cox's proportional hazard analysis revealed that HD duration (HR 1.08 per year, 95 % CI 1.03-1.13, P = 0.002), β-blocker use (0.28, 0.17-0.46, P < 0.001), and diabetes mellitus (2.10, 1.23-3.56, P = 0.007) were independent predictors of MACE. Longer HD duration did not affect TLR; however, SCD was significantly higher in the long HD duration group.

show abstract

“…Yano et al. published a small study where they were looking at inflammatory markers after implantation of PES and SES in hemodialysis population . They showed that high‐sensitivity C‐reactive protein (hs‐CRP) as well as interleukin 6 (IL‐6) decreased significantly post‐PES implantation, but not after SES.…”

Section: Discussionmentioning

confidence: 99%

Treatment of symptomatic coronary artery disease in patients with end‐stage renal disease on hemodialysis with paclitaxel‐eluting TAXUS stent

Wiernek

Kiesz

Wiernek

et al. 2015

Hemodialysis International

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) utilizing drug-eluting stents is becoming a very common revascularization technique in the dialysis cohort; therefore, we sought to identify the impact of dialysis on outcomes in this group of patients. This is a multicenter registry comparing results of 290 patients (186 with normal kidney function, 104 on dialysis) who underwent PCI with exclusive use of paclitaxel-eluting TAXUS stent. The primary endpoint was an assessment of major adverse cardiac events (MACE) at 1-and 2-year observation. Mean follow-up was 23.3 ± 6.1 months. Results at 12 months showed: MACE 11.8% vs. 7.7% (P = not significant [ns]), composite major adverse cardiac and cerebrovascular events (MACCE) 12.4% vs. 11.5% (P = ns), all-cause death 2.7% vs. 8.6% (P < 0.05), cardiac death 2.7% vs. 1.9% (P = ns), target vessel revascularization (TVR) 9.1% vs. 6.7% (P = ns), acute myocardial infarction (AMI) 3.8% vs. 2.9% (P = ns), cerebrovascular events (CVA) 0.5% vs. 1.0% (P = ns); and results at 24 months showed: MACE 17.7% vs. 18.3% (P = ns), MACCE 21.5% vs. 26.0% (P = ns), all-cause death 4.3% vs. 14.4% (P < 0.01), cardiac death 3.2% vs. 1.9% (P = ns), TVR 14.0% vs. 16.3% (P = ns), AMI 5.4% vs. 5.8% (P = ns), CVA 3.2% vs. 2.9% (P = ns) for non-endstage renal disease (ESRD) and dialysis group, respectively. Prior coronary artery bypass graft (CABG) was found to be single risk factor for MACE, TVR, and MACCE in patients with ESRD, while dialysis and prior CABG were found to be single risk factors for death in the entire population. PCI with TAXUS is a feasible procedure and presents promising results in dialysis-dependent patients.

show abstract

Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis

Cited by 12 publications

References 34 publications

C-Reactive Protein and Inflammatory Cytokines during Percutaneous Coronary Intervention

C-Reactive Protein and Inflammatory Cytokines during Percutaneous Coronary Intervention

Influence of hemodialysis duration on mid-term clinical outcomes in hemodialysis patients with coronary artery disease after drug-eluting stent implantation

Treatment of symptomatic coronary artery disease in patients with end‐stage renal disease on hemodialysis with paclitaxel‐eluting TAXUS stent

Contact Info

Product

Resources

About